Abstract
Objectives We sought to compare two of the most promising plasma biomarkers for Alzheimer disease (AD): pTau181 and pTau217.
Methods pTau181 and pTau217 were quantified using, Quanterix and ALZpath, SIMOA assays in the well characterized prospective multicentre BALTAZAR cohort of mild cognitive impairment (MCI) participants.
Results Among MCI participants, 55% were Aβ+ and 29% developed dementia due to AD. pTau181 and pTau217 were higher in the Aβ+ population with fold-change of 1.5 and 2.7 respectively. MCI that converted to AD also had higher levels than non-converters, with hazard ratios of 1.38 (1.26-1.51) for pTau181 compared to 8.22 (5.45-12.39) for pTau217. The AUC for predicting Aβ+ was 0.783 (95%CI: 0.721-0.836; cut-point 2.75 pg/mL) for pTau181 and 0.914 (95%CI: 0.868-0.948; cut-point 0.44 pg/mL) for pTau217. The high predictive power of pTau217 was not improved by adding age, sex, and APOEε4 status, in a logistic model. Age, APOEε4 and renal dysfunction were associated with pTau levels, but the clinical performance of pTau217 was only marginally altered by these factors. Using a two cut-point approach, a 95% positive predictive value for Aβ+ corresponded to pTau217 > 0.8 pg/mL and a 95% negative predictive value at <0.23 pg/mL. At these two cut-points, the percentages of MCI conversion were 56.8% and 9.7% respectively, while the annual rates of decline in MMSE were −2.32 versus −0.65.
Conclusions Plasma pTau217 and pTau181 both correlate with AD, but the fold-change in pTau217 make it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The French ministry of Health (Programme Hospitalier de Recherche Clinique), Grant/Award Numbers:PHRC2009/01-04,PHRC-13-0404; The Foundation Plan Alzheimer; Fondation pour la Recherche Medicale (FRM); The Gerontopole Ile de France (GERONDIF). None of the funding bodies had any role in study design, in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent to be part of the study. The BALTAZAR study was approved by the Paris ethics committee (CPP Ile de France IV Saint-Louis Hospital). Clinical trial registration: NCT01315639
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Following review, correction of English, addition of supplementary figures and tables. No modification of main conclusion or authorship.
